● Ravi Mehrotra Global Research Impact Profile

MD, DPhil, FRCPath

Cancer prevention | Precision oncology | Genomics | Global implementation science

Translating cancer science into international standards and population impact

Physician-scientist and global cancer leader connecting pathology, prevention, population research, genomics and implementation. Scopus profile: 334 documents, h-index 66 and 69,747 citations (14 September 2026).

★ 1. Cancer genomics and precision oncology

Advanced population-relevant cancer genomics by linking molecular evidence, pathology and clinically annotated data for underrepresented populations.

ROLE First author of an international gallbladder-cancer genomics synthesis; last author of the OrCanome oral-cancer resource paper; Board Director of the Indian Cancer Genome Atlas Foundation.

RESULTING IMPACT Helped frame an internationally informed genomics agenda while supporting data resources needed for more equitable precision oncology.

— SELECTED LANDMARK PUBLICATIONS

- FIRST AUTHOR | Mehrotra R et al. Genetic landscape of gallbladder cancer: Global overview. Mutat Res Rev Mutat Res. 2018;778:61-71. PMID 30454684.
- LAST AUTHOR | Bhartiya D et al. OrCanome: a Comprehensive Resource for Oral Cancer. Asian Pac J Cancer Prev. 2016;17:1333-1336. PMID 27039767.

★ 2. Global diagnostic standards, policy and institutional capacity

Connected scientific evidence with international diagnostic standardisation, research governance, policy translation and professional capacity building.

ROLE Standing Board member and series editor for the IAC-IARC-WHO Cytopathology Reporting Systems; former member, IARC Scientific Council; last and corresponding author of international work on strengthening affordable cytopathology and diagnostic capacity in resource-constrained countries.

RESULTING IMPACT Contributed to globally applicable cytopathology terminology and diagnostic-management frameworks while building bridges among researchers, clinicians, policymakers and public-health organisations.

— SELECTED LANDMARK PUBLICATIONS

- STANDING BOARD / SERIES EDITOR; CO-AUTHOR | Field AS et al. The rationale for the development and publication of the World Health Organization reporting systems for cytopathology. Cancer Cytopathol. 2023;131:751-761. DOI 10.1002/cncy.22757.
- LAST AND CORRESPONDING AUTHOR | Yadav K et al. Importance of Cytopathologic Diagnosis in Early Cancer Diagnosis in Resource-Constrained Countries. JCO Global Oncology. 2022;8:e2100337. PMID 35213215.

★ 3. Global tobacco control and oral cancer prevention

Integrated pathology, epidemiology and public policy to address smokeless tobacco and oral cancer across diverse regulatory and disease-burden settings.

ROLE First author of the 180-country Lancet Oncology policy review; last author of a systematic global review and meta-analysis spanning four WHO regions.

RESULTING IMPACT Established a cross-national benchmark for WHO FCTC implementation and strengthened the global evidence base linking smokeless-tobacco products with oral-cancer risk.

— SELECTED LANDMARK PUBLICATIONS

- FIRST AUTHOR | Mehrotra R et al. Smokeless tobacco control in 180 countries across the globe: call to action for full implementation of WHO FCTC measures. Lancet Oncol. 2019;20:e208-e217. PMID 30942182.
- LAST AUTHOR | Asthana S et al. Association of Smokeless Tobacco Use and Oral Cancer: A Systematic Global Review and Meta-Analysis. Nicotine Tob Res. 2019;21:1162-1171. PMID 29790998.

★ 4. Oral cancer prevention, screening and workforce capacity

Connected international evidence evaluation with practical approaches to screening, early diagnosis and workforce development in resource-constrained settings.

ROLE Member of the IARC Handbook Volume 19 Working Group Co-chair and author of the NEJM IARC Perspective; last and corresponding author of Project ECHO cancer-screening research.

RESULTING IMPACT Contributed to IARC's authoritative international evaluation of oral-cancer prevention and demonstrated that telementoring can sustain screening knowledge where specialist access is limited.

— SELECTED LANDMARK PUBLICATIONS

- IARC WORKING-GROUP CO-AUTHOR | Bouvard V et al. IARC Perspective on Oral Cancer Prevention. N Engl J Med. 2022;387:1999-2005. PMID 36378601.
- LAST AND CORRESPONDING AUTHOR | Hariprasad R et al. Retention of Knowledge Levels of Health Care Providers in Cancer Screening Through Telementoring. J Glob Oncol. 2018;4:1-7. PMID 30084700.

★ 5. Global disease burden and cancer prevention equity

Contributed regional expertise and senior authorship to international studies quantifying preventable disease burden and disparities across populations.

ROLE Named GBD 2023 Second-hand Smoke Collaborator; last author of a global systematic review and meta-analysis of mortality attributable to smokeless tobacco.

RESULTING IMPACT Supported comparable evidence across 204 countries and territories and strengthened the case for equitable tobacco-control and cancer-prevention policies worldwide.

— SELECTED LANDMARK PUBLICATIONS

- [COLLABORATIVE AUTHOR | GBD 2023 Second-hand Smoke Collaborators. Global, regional, and national](https://pubmed.ncbi.nlm.nih

★ Current research agenda

Precision cancer prevention: integrating genomics, pathology, epidemiology, behavioural risks and implementation science to create affordable, scalable and equitable approaches for diverse populations.

Verified research profiles

- Scopus | Author ID 7203045563
- ORCID | 0000-0001-9453-1408
- Google Scholar | Public citation profile
- Research Impact webpage | CHIP Foundation